| Joel A Alcid, MD | |
|
201 Route 17 Fl 11, Rutherford, NJ 07070-2557 | |
| (201) 500-4958 | |
| (833) 993-1986 |
| Full Name | Joel A Alcid |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 8 Years |
| Location | 201 Route 17 Fl 11, Rutherford, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114248002 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | MT211663 (Pennsylvania) | Secondary |
| 207RH0003X | Internal Medicine - Hematology & Oncology | 25MA11388100 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Mary's General Hospital | Passaic, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Titan Health Partners Llc | 3971915349 | 58 |
News Archive
Oncolytics Biotech Inc. announced today that it has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN in patients with advanced or metastatic colorectal cancer.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has announced the release of new health information to raise awareness about diabetes, digestive diseases, and kidney and urologic diseases among people not yet diagnosed with these illnesses.
Toshiba Corporation and a team led by Professor Yozo Nakazawa at the Department of Pediatrics, Shinshu University, have together developed a "tumor-tropic liposome technology" for gene therapy. The technology uses unique, nano-sized biodegradable liposomes developed by Toshiba to accurately and efficiently deliver therapeutic genes to targeted cancer cells, and achieves safer gene delivery than viruses used as carriers.
Researchers in the United States have warned that as of July 15th this year (2021), the level of population immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – may still have been insufficient to contain infection outbreaks and safely return to pre-pandemic social behavior.
› Verified 2 days ago
| Entity Name | Titan Health Partners Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790396281 PECOS PAC ID: 3971915349 Enrollment ID: O20201209002560 |
News Archive
Oncolytics Biotech Inc. announced today that it has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN in patients with advanced or metastatic colorectal cancer.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has announced the release of new health information to raise awareness about diabetes, digestive diseases, and kidney and urologic diseases among people not yet diagnosed with these illnesses.
Toshiba Corporation and a team led by Professor Yozo Nakazawa at the Department of Pediatrics, Shinshu University, have together developed a "tumor-tropic liposome technology" for gene therapy. The technology uses unique, nano-sized biodegradable liposomes developed by Toshiba to accurately and efficiently deliver therapeutic genes to targeted cancer cells, and achieves safer gene delivery than viruses used as carriers.
Researchers in the United States have warned that as of July 15th this year (2021), the level of population immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – may still have been insufficient to contain infection outbreaks and safely return to pre-pandemic social behavior.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joel A Alcid, MD 629 Cranbury Rd Fl 2, East Brunswick, NJ 08816-4096 Ph: (732) 390-7750 | Joel A Alcid, MD 201 Route 17 Fl 11, Rutherford, NJ 07070-2557 Ph: (201) 500-4958 |
News Archive
Oncolytics Biotech Inc. announced today that it has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN in patients with advanced or metastatic colorectal cancer.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has announced the release of new health information to raise awareness about diabetes, digestive diseases, and kidney and urologic diseases among people not yet diagnosed with these illnesses.
Toshiba Corporation and a team led by Professor Yozo Nakazawa at the Department of Pediatrics, Shinshu University, have together developed a "tumor-tropic liposome technology" for gene therapy. The technology uses unique, nano-sized biodegradable liposomes developed by Toshiba to accurately and efficiently deliver therapeutic genes to targeted cancer cells, and achieves safer gene delivery than viruses used as carriers.
Researchers in the United States have warned that as of July 15th this year (2021), the level of population immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – may still have been insufficient to contain infection outbreaks and safely return to pre-pandemic social behavior.
› Verified 2 days ago
Dr. Eleanor A Gonnella, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 47 Orient Way, Suite 3b, Rutherford, NJ 07070 Phone: 201-939-2826 Fax: 201-939-0562 | |
Dr. Kathleen M Kaelin Wooton, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 223 Woodward Ave, Rutherford, NJ 07070 Phone: 201-964-1806 | |
David L Isralowitz, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 128 Union Ave, Rutherford, NJ 07070 Phone: 201-939-8834 Fax: 201-939-7644 | |
Dr. Kenneth Zierer, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 71 Union Ave Ste 201, Rutherford, NJ 07070 Phone: 201-842-0020 Fax: 201-842-0010 | |
Dr. Andrew The, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 130 Orient Way Ste Bb, Rutherford, NJ 07070 Phone: 201-438-6916 Fax: 201-438-4227 | |
Jaroslaw S Pondo, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 71 Union Ave, Suite 107, Rutherford, NJ 07070 Phone: 201-896-0050 Fax: 201-896-0051 |